Navigation Links
QRxPharma Limited Announces A$14 Million Placement Together With a Share Purchase Plan
Date:10/1/2010

therefore cause actual results to differ materially from those contained in any forward-looking statement.  Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization of the Company's proposed products.

About QRxPharma

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes.  The Company intends to co-promote its products in the US and seeks strategic partnerships for worldwide markets. QRxPharma's lead product candidate, MoxDuo®IR, is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equi-analgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain. QRxPharma expects to complete its Phase 3 program in Q4 CY2010 and file its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for MoxDuo IR in Q1 CY2011. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, visit www.qrxpharma.com.


'/>"/>
SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013  Sony Biotechnology Inc. ... SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting and ... will be held at the San Diego ... California , from May 20 - 22.  ... analytical system, incorporating commercial audio-visual technologies into new and ...
(Date:5/17/2013)... announced that it will report its 2013 first quarter earnings on Wednesday, ... Ed Borkowski , CFO, will host an analyst and investor ... participate in the conference call within the U.S. and Canada ... call outside the U.S. and Canada , dial (760) ... should dial in 10 minutes prior to the start of the call. ...
(Date:5/17/2013)... , May 17, 2013  Boehringer Ingelheim will ... disease at the American Thoracic Society International Conference ... , May 17 – 22. Data ... for the treatment of chronic obstructive pulmonary disease ... well as investigational compounds for asthma, idiopathic pulmonary ...
Breaking Medicine Technology:Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8
... Influenza Conference, HIGH WYCOMBE, England, June 18, 2007 ... new flu vaccine has the,potential to protect against ... presented today by PepTcell, at the 2007,Options for ... Canada. , The pre-clinical results, which will be ...
... 18, 2007-Active Biotech (OMX Nordic: ACTI),has presented ... the 8th,World Congress on Inflammation (<a target="_blank" ... "The results strengthen the further clinical development ... show the possibility to reduce,the use of ...
Cached Medicine Technology:New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 2New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 3New Flu Vaccine From PepTcell Could Provide Immunity Against All,Strains of Influenza Virus 4Active Biotech presents new pre-clinical data for the 57-57 project,at the 8th World Congress on Inflammation 2
(Date:5/19/2013)... Keith Chertok now provides gum disease patients with a new ... chance of a healthier smile. Laser gum surgery ... removes diseased gum tissue in patients, but it also stimulates ... implants. , LANAP uses a laser to successfully treat ... the healthy tissue as well as encourage new bone growth. ...
(Date:5/19/2013)... Nevada (PRWEB) May 19, 2013 Vegas ... , is proud to announce the launch it's all ... at the MGM Grand on 5/19/2013. Consumers traveling to ... new special pricing available on VegasHotelEscapes.com's website. Travelers will ... they beat any competitors price. , Vegas Hotel Escapes ...
(Date:5/19/2013)... Agora Health Limited developed by Rachael Linkie ... how to increase memory power naturally and effectively. ... helps people re-new their entire health from the inside out. ... by a fatigued mind. In addition, the program helps people ... lifetime. The author claimed that this program can help people ...
(Date:5/19/2013)... Passages Malibu, the leading non-12 step, holistic, and ... the launch of a “Sobriety, Health, and Wellness” survey ... “We are always looking for new ways to engage ... regarding sobriety, what’s working for people, and what isn’t,” ... Passages Addiction Treatment Centers located in Malibu and ...
(Date:5/19/2013)... Argentina: Yoga classes ( clases de Yoga ) will ... Sivananda Yoga Vedanta Center. The center is located ... are 90 minutes and are offered all week long. ... environment, allowing visitors to enjoy the benefits of Yoga, ... , The Yoga classes follow the following principles: , ...
Breaking Medicine News(10 mins):Health News:Berkeley, CA Periodontist, Dr. Keith Chertok Now Treats Gum Disease Patients With Laser Gum Surgery Prior to Placing Dental Implants 2Health News:How To Increase Memory Power | How “Agora Health Limited” Helps People Improve Their Memory Naturally And Effectively – Health Review 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 2Health News:Passages Malibu Announces its Sobriety, Health, and Wellness Social Media Survey 3Health News:Clases de Yoga in Buenos Aires, Argentina (Yoga Classes) Now Offered by Sivananda Yoga Vedanta Center 2
... UTRECHT, The Netherlands, November 2 InteRNA Technologies,B.V. ... entered into a,research agreement to develop microRNA (miRNA)-based ... Under the research collaboration with Associate Professor William ... unique,lentiviral-based miRNA overexpression library will be applied in,multi-parametric, ...
... ... cigarette cartridge, may prevent pneumonia, influenza, and other respiratory diseases. These findings are based ... of Chicago,s Billings Hospital in 1942 on inhalation of vaporized propylene glycol in laboratory ... (PRWEB) ...
... Driving Prevention Week(R) to Prevent Fall-Asleep Crashes With Tips and Countermeasures ... as a major contributor to vehicle crashes. The National Sleep Foundation,s ... as many as 1.9 million drivers have had a car crash ... Even more surprising, 54% of drivers (105 million) have driven while ...
... 5, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. ... CTIC) management team will host a conference call to discuss ... Conference Call Numbers, Thursday, November ... a.m. Pacific Time, 1-877-941-6010 (US Participants), ...
... England, Nov. 1 THURSDAY saw over 100 people, ... Celebrity MasterChef winner Liz McClarnon and model Charlotte Mears, ... cosmetic surgery clinic from Transform. The new state of ... now the 22nd cosmetic surgery clinic by Transform - ...
... , SUNDAY, Nov. 1 (HealthDay News) -- Dialysis patients with very ... people on dialysis, even those with the highest levels of body ... percentage in 671 dialysis patients in California. In the next five ... body fat was 2½ to three times higher than it was ...
Cached Medicine News:Health News:InteRNA Technologies and Dana-Farber Cancer Institute to Collaborate on the Role of microRNAs in Cancer Pathways 2Health News:Vaporized Propylene Glycol, a Key Ingredient in Electronic Cigarettes, May Prevent Pneumonia, Influenza, and Other Respiratory Diseases 2Health News:1.9 Million Drivers Have Fatigue-Related Car Crashes or Near Misses Each Year 2Health News:1.9 Million Drivers Have Fatigue-Related Car Crashes or Near Misses Each Year 3Health News:1.9 Million Drivers Have Fatigue-Related Car Crashes or Near Misses Each Year 4Health News:Nicky Hambleton-Jones Supports Launch of State-of-the-Art London Cosmetic Surgery Clinic 2
The Antibacterial Personal Catheter® features a unique silicone composition that provides an antibacterial coated soft outer layer of silicone combined with a firm inner layer....
... on delicate urethral tissues. The ... coating provide nearly friction-free movement, ... easy to maintain sterility. You ... its own sterile water, avoiding ...
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... Pak Seven Starter Kit: a ... of Freedom Clear catheters and ... 100% latex-free along with ... convenience and comfort. Plus each ...
Medicine Products: